Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma
Clinical trial NCT03343665 · COMPLETED
Trial details
- NCT number
- NCT03343665
- Sponsor
- St. Petersburg State Pavlov Medical University
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-01
- Primary completion
- 2019-12-20
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.